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Abstract
Fibrosis is the histological manifestation of a progressive usually irreversible process causing 
chronic and end stage kidney disease. Genome-wide transcriptome studies of a large cohort (n=95) 
of normal and fibrotic human kidney tubule samples followed by systems and network analyses 
identified inflammation and metabolism as top dysregulated pathways in diseased kidneys. In 
particular, we found that humans and mouse models with tubulointerstitial fibrosis had lower 
expression of key enzymes and regulators of fatty acid oxidation (FAO) and increased intracellular 
lipid deposition. In vitro experiments indicated that inhibition of fatty acid oxidation in tubule 
epithelial cells caused ATP depletion, cell death, dedifferentiation and intracellular lipid 
deposition; a phenotype observed in fibrosis. Restoring fatty acid metabolism by genetic or 
pharmacological methods protected mice from tubulointerstitial fibrosis. Our results raise the 
possibility that correcting the metabolic defect may be useful for preventing and treating chronic 
kidney disease.
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Introduction
Fibrosis is the final common pathway and the histological manifestation of chronic kidney 
disease (CKD)1. While glomerular lesions are specific for the disease etiology, fibrosis 
shows almost identical manifestation in all progressive CKD2. Fibrosis is characterized by 
loss of capillary networks, accumulation of fibrillary collagens, activated myofibroblasts and 
inflammatory cells3,4. In fibrosis, tubular epithelial cells (TECs) are lost due to cell death 
and the remaining cells dedifferentiate leading to reduced expression of characteristic 
epithelial markers and increased expression of mesenchymal markers. Increased tubular 
epithelial Notch, Wnt and Hedgehog signaling can induce dedifferentiation of TECs, a 
critical characteristic of CKD5–7. While TECs may not be the direct precursors of 
myofibroblasts, they play an instrumental role in orchestrating fibrosis by multiple 
mechanisms including secreting different cytokines. Transforming growth factor beta 
(TGFB1) is a key mediator of tissue fibrosis; it induces secretion of fibrillary collagens, and 
promotes cell death and dedifferentiation8.
Alteration in cellular metabolism, including changes in fuel source preferences (glucose, 
fatty acids or ketones) has emerged as an important mechanism of cell differentiation, 
especially in the context of stem cells and carcinogenesis9. Metabolic reprogramming is a 
critical constituent of malignant transformation. Many cancers have increased glucose 
uptake and reduced mitochondrial glucose oxidation, a phenomenon called the “Warburg 
effect”. Very little is known about the metabolism of renal epithelial cells10,11. Proximal 
TEC have high levels of baseline energy consumption and a copious supply of 
mitochondria. Fatty acid oxidation (FAO) is the preferred energy source for highly 
metabolic cells like cardiac myocytes because it generates more ATP than does oxidation of 
glucose.
The uptake of long chain fatty acids is facilitated by the long chain fatty acid transporter; 
cluster of differentiation 36 (CD36)12. Metabolism of fatty acids requires their transport into 
the mitochondria, which is mediated by carnitine palmitoyl-transferase 1 (CPT1) and this 
enzyme conjugates fatty acids with carnitine13. CPT1 is considered to be the rate-limiting 
enzyme in FAO. The peroxisome proliferator-activated receptors (PPAR) and PPARgamma 
coactivator-1a (PPARGC1A) are the key transcription factors that regulate the expression of 
proteins involved in fatty acid uptake and oxidation14–16. Normally, fatty acid uptake, 
oxidation and synthesis are tightly balanced to avoid intracellular lipid accumulation.
Tubule epithelial lipid accumulation has received significant attention especially in the 
context of acute and diabetic kidney disease17–20. It has been proposed that excess 
accumulation of triglyceride induce cellular lipotoxicity potentially contributing to fibrosis 
development17–20. For this reason, we were alerted when our unbiased gene profiling 
highlighted alterations in cellular metabolism in fibrotic kidneys. We uncovered that 
enzymes and regulators of FAO were reduced in kidneys from human subjects with CKD 
and in mouse models of kidney fibrosis. We found that healthy renal TECs primarily rely on 
FAO as their energy source. Lower FAO by TECs appears to contribute to tubulointerstitial 
fibrosis development and therefore restoring FAO may be beneficial for treatment of CKD.
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RESULTS
The transcriptional landscape of human CKD samples highlighted dyregulation in cellular 
metabolism
To examine genome wide transcript level changes in human samples with CKD we collected 
and analyzed a large number (n=95) of microdissected human kidney samples21,22. As the 
patterns of diabetes- and hypertension-induced tubulointerstitial fibrosis are almost 
indistinguishable, we performed a combined analysis of tubulointerstitial samples obtained 
from diabetic and hypertensive CKD samples (Supplementary Table 1). Cases were defined 
based on their glomerular filtration rate (<l60cc/min/1.72m2) and by the presence of 
histological lesions of fibrosis. The analysis allowed us to identify common patterns and 
pathways that characterize CKD in human subjects. We identified 2,497 transcripts with a 
corrected p-value of 0.05 and at least 30% change in their expression values (Supplementary 
Fig. 1 and Supplementary Table 2). Diabetic and hypertensive CKD samples showed similar 
changes.
High-level pattern analysis, using gene ontology tools, highlighted the differential regulation 
of two key pathways, inflammation and metabolism. Inflammation is known to play an 
important functional role in fibrosis development (Fig. 1a)23. On the other hand, we also 
detected a very robust signal indicating the dysregulation of cellular metabolism in CKD 
(Fig 1a and Supplementary Fig. 2). Gene ontology analysis highlighted specific changes in 
fatty acid metabolism, beta-oxidation, amino acid catabolism, and carbohydrate metabolism 
(Fig 1a). Gene set enrichment analysis confirmed the strong enrichment for FAO amongst 
the differently expressed pathways (Fig. 1b,c and Supplementary Fig. 2). A more detailed 
interrogation indicated that genes related to fatty acid metabolism and their key 
transcriptional regulator complex PPARA/PPARGC1A were markedly lower in CKD 
samples (Fig. 1d–f). There was also a considerable reduction in levels of key regulators of 
glucose utilization (Fig. 1g). The lower expression of key FAO regulators was associated 
with higher lipid accumulation in diseased renal TECs (Fig. 1e). Several mitochondrial 
enzyme and transcription factor mRNA levels were lower in CKD samples, but we found no 
difference in mitochondrial DNA copy number (Supplementary Fig. 3a,b). In summary, 
genome wide unbiased transcript analysis of one of the largest collections of human kidney 
samples identified that enzymes and critical regulators of FAO are lower in kidneys with 
fibrosis.
Genome-wide transcriptome analyses of mouse models of fibrosis indicated differences in 
FAO
Next, we analyzed genome wide transcriptional changes in mouse models of fibrosis. First, 
we examined a genetic model of fibrosis created by transgenic overexpression of the Notch1 
intracellular domain in TECs by using a doxycycline inducible transgenic system 
(Tetracycline Responsive Element Intra-Cellular Notch1 [TRE-ICNotch1]) (Supplementary 
Fig. 4a). Induction of this transgene causes severe tubulointerstitial fibrosis (TIF) (Fig. 2a)5. 
Transcriptome analysis of control and Pax8rtTA/TREICNotch1 kidneys was accomplished 
using the Affymetrix ST1.0 platform5. Gene ontology analysis again indicated coordinated 
differences in metabolic pathways (Fig. 2b). We observed alterations in amino acid, 
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carbohydrate and fatty acid metabolism. Transcript levels of key and rate limiting enzymes 
of FAO (Cpt, Acox) and glucose utilization (Pgk, Pk) were markedly lower in this mouse 
fibrosis model (Fig. 2c,d). Immunostaining studies confirmed the lower expression of Ppara; 
a key regulator of lipid metabolism (Fig 2a).
Similar changes were observed in kidneys from mice with folic acid-induced kidney fibrosis 
(FAN). Protein and transcript levels of key FAO enzymes were lower (Fig. 2e). Ppara and 
Ppargc1a mRNA levels were lower (Fig. 2f,g) and lipid accumulation (Fig. 2f) and 
triglyceride content (Fig. 2h) were higher in TEC of FAN mice. Mitochondrial copy number 
was not changed, but the expression of several mitochondrial specific genes was lower in 
kidneys from mice with FAN (Supplementary Fig. 3c,d). Time-course experiments indicated 
that the lower expression of FAO in the FAN model preceded the expression of fibrosis 
markers (Supplementary Fig. 5a–c), potentially suggesting its causal role. Thus, mouse 
models of kidney fibrosis showed similar metabolic changes to human CKD samples: low 
fatty acid and carbohydrate metabolism and high intracellular lipid accumulation.
The role of tubule epithelial lipid accumulation in CKD development
Tubule epithelial lipid accumulation was evident both in kidneys from mice and humans 
with renal fibrosis. It has been proposed that increased lipid accumulation leads to 
lipotoxicity, contributing to fibrosis development24. Long-chain fatty acids particularly 
palmitate and stearate mostly enter cells via the long-chain fatty acid transporter (CD36)12. 
To test this hypothesis we generated a mouse model with kidney specific overexpression of 
CD36. We placed the human CD36 under a tetracycline responsive element (TRE) and 
crossed the animals with the Pax8rtTA animals. Upon doxycycline administration (at 4 
weeks of age), the expression of human CD36 was induced in TEC (Fig. 3a and 
Supplementary Fig. 4b). By 8 weeks of age, we observed considerable accumulation of 
intracellular lipids (Fig. 3b) and triglycerides in the Pax8rtTA/TRECD36 animals compared 
to controls (Fig. 3c). We performed fatty acid quantification by GC/FID (gas 
chromatography followed by flame ion diffusion), which indicated that the major fatty acid 
subtypes in the mouse kidney were stearic, palmitic, linoleic and docosohexaenoic acid (Fig. 
3d, Supplementary Table 3). Levels of stearate and palmitate were markedly higher in 
double transgenic animals compare to WT animals (Supplementary Table 3). The 
concentration of short chains fatty acids was slightly lower in double transgenic kidney 
samples. Quantitative analysis of markers of FAO indicated no change or only slightly 
higher expression of Cpt1a mRNA level by 20 weeks of age (Fig. 3e).
Eight-week-old CD36 transgenic animals (at the time when fatty acid accumulation was 
already evident) showed no evidence of profibrotic marker expression (Fig. 3f), Sirius red 
staining (Fig. 3b) and change in levels of apoptosis related genes (Fig. 3g). By 20 weeks of 
age we observed slightly higher expression of Acta2 and Col1a (Fig. 3f). CD36 transgenic 
animals did not show higher susceptibility to diabetic kidney injury induced by 
streptozotocin (Supplementary Fig. 6) or folic acid induced fibrosis (data not shown). In 
summary, CD36 overexpression led to TEC lipid accumulation, but this high lipid 
(triglyceride and long chain fatty acid) levels alone was not sufficient to induce the full 
spectrum of fibrosis. We hypothesized that reduced fatty acid utilization (FAO) is the major 
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inciting factor for fibrosis development and that lipid accumulation occurred as a secondary 
consequence.
Renal TECs mostly depend of FAO as their energy source
The metabolic derangement observed in patient samples with fibrosis prompted us to 
examine the metabolic pattern of TECs. To quantitatively analyze metabolism we examined 
oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of primary 
TECs and a TEC cell line; HKC-8 (Supplementary Fig. 7, Fig. 4a,b). We found that OCR 
was markedly higher when palmitic acid was presented to TECs, indicating that TECs 
efficiently metabolize palmitate. The increase in OCR was sensitive to the Cpt1 inhibitor 
etoxomir, confirming its specificity (Fig. 4a). OCR was unchanged after glucose injection 
(Fig. 4b). On the other hand, ECAR was higher following glucose injection, indicating that 
glucose is mainly used for anaerobic glycolysis (lactate causes acidosis, but does not 
consume oxygen) (Fig. 4b). FAO is the key contributor to intracellular ATP levels as 
etoxomir treatment markedly reduced intracellular ATP content in TEC (Fig. 4c). Etomoxir 
treatment was also associated with higher apoptosis rate, i.e. more cleaved caspase 3 
positive cells and lower anti-apoptotic BCL2 transcript levels (Fig. 4d,e). Inhibition of FAO 
caused dedifferentiation of TECs–including the expression of ACTA2, VIM, COL1A1 and 
COL3A1 (Fig. 4f)–and higher intracellular lipid droplet accumulation (Fig. 4d). Similar 
results were observed with ranolazine, a partial FAO inhibitor (Supplementary Fig. 8a–c). In 
summary, we found that blockade of FAO was associated with higher cell death, 
dedifferentiation and intracellular lipid accumulation, a phenotype that mimicked what we 
had observed in human fibrotic kidneys.
Transforming growth factor beta (TGFB1) suppresses FAO in a SMAD3 and PPARGC1A 
dependent manner
TGFB1 is one the most powerful profibrotic cytokine; therefore we next examined the effect 
of TGFB1 on renal epithelial cell metabolism. As described previously, treatment of TEC’s 
with TGFB1 induced clear profibrotic phenotypic changes characterized by loss of epithelial 
phenotype and acquisition of a mesenchymal markers (expression of COLa1, COL3a1, VIM, 
FN and ACTA2 (Supplementary Fig. 8d,e)25. Cells treated with TGFB1 had lower baseline 
of oxygen consumption levels and they showed a reduction in palmitate-induced elevation in 
OCR, indicating a low activity of fatty acid metabolism (Fig. 4g). TGFB1 reduced PPARA 
and PPARGC1A mRNA levels and their downstream targets CPT1 and ACOXs, which was 
the likely cause for the lower expression of FAO (Fig. 4h). Consistent with the significant 
metabolic depression, there was an accumulation of oil-red-o positive lipids (Fig. 4i) and 
lower cellular ATP content (Fig. 4j) in TGB1 treated cells. Levels of glucose metabolism 
related enzymes (PFK1 and PK) (Supplementary Fig. 8f) were lower in TGFB1 treated 
cells. Therefore, TGFB1 induces a metabolic reprogramming in TECs, specifically lower 
FAO and higher lipid accumulation.
Next, we analyzed the molecular mechanism of the TGFB1-induced FAO blockade. We 
found that TGFB1’s effects were Smad3 dependent. TGFB1 did not change transcript levels 
of fatty acid metabolism related enzymes (Cpt, Acox Ppara and Ppargc1a) in Smad3 
deficient renal tubule cells (Supplementary Fig. 8g,h). Furthermore using publicly available 
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chromatin immunoprecipitation and sequencing (ChIP-Seq) data we identified that SMAD3 
directly binds to an intronic area on the PPARGC1A gene (Fig. 5a) (GSE29422)26. This 
intronic area is outside of the promoter region of PPARGC1A, and does not overlap with 
active promoter specific histone tail modifications (H3K4me3) in human kidney TECs27. On 
the other hand it overlapped with active enhancer specific histone tail modifications 
(H3K4me1) and this region was a computationally annotated active enhancer (by 
ChromHMM-based) region in human kidney TECs (Fig. 5a)27. PPARGC1A is a critical 
transcription factor that regulates mitochondrial biogenesis and the expression of almost all 
rate-limiting enzymes in the FAO pathway. We did not observe direct SMAD3 binding to 
PPARA. These results indicate that TGFB1 via SMAD3 can potentially directly regulate 
PPARGC1A transcript levels.
We next tested whether the TGFB1-induced metabolic reprogramming was mediated by 
Ppargc1a using primary murine proximal TECs from mice with tubule specific 
overexpression of Ppargc1a (Pax8rtTA/TRE-Ppargc1a mice [see description later]). 
Ppargc1a transgenic cells showed no difference in their palmitate induced oxygen 
consumption rate after TGFB1 treatment (Fig. 5b). Genetic overexpression of Ppargc1a 
normalized transcript levels of Cpt and other FAO enzymes (Fig. 5c), however, the defect in 
glucose utilization related gene expression was not recovered in transgenic cells (Fig. 5d). 
These results indicate that the TGFB1 induced FAO blockade is mediated by Ppargc1a.
Next, we examined whether metabolic reprogramming plays a role in the TGFB1-induced 
profibrotic phenotype development. We found that Ppargc1a transgenic cells were protected 
from TGFB1-induced functional changes including the expression of profibrotic (Col3a1, 
Fn, Acta2, and Col4a1) and apoptosis-associated (Bcl2) gene expression (Fig. 5e,f). These 
results indicate that metabolic reprogramming plays a critical role in the TGFB1-induced 
functional changes.
As Ppargc1a acts together with Ppara to regulate FAO, next we examined the effect of the 
Ppara agonist, fenofibrate. Fenofibrate normalized TGFB1-induced FAO repression (Fig. 
5g), Cpt1 and Acox reduction (Fig. 5h), but not the glucose utilization defect (Fig. 5i). It 
ameliorated TGFB1-induced dedifferentiation and apoptosis (Fig. 5j). Thus, the TGFB1-
induced and Smad3-mediated repression of Ppargc1a and FAO are critical components of 
the TGFB1-induced TECs dedifferentiation and apoptosis.
Genetic or pharmacological improvement of FAO protected animals from kidney fibrosis 
development in vivo
We next tested whether improving FAO in vivo in mouse models protects animals from 
tubulointerstitial fibrosis development. We used both transgenic and pharmacological 
approaches to achieve our goals. First, we analyzed the effect of transgenic overexpression 
of Ppargc1a. This was achieved by intercrossing the Pax8rtTA animals with the TRE/
Ppargc1a animals. Single and double transgenic animals were fed with doxycycline 
containing food starting at 4 weeks of age. Tubulointerstitial fibrosis was induced by folic 
acid administration at 6 weeks of age. Double transgenic animals showed improvement in 
renal histology as shown by the PAS stained kidney sections and QRT-PCR based 
quantification of profibrotic molecules (Fig. 6a,b). Transgenic expression of Ppargc1a 
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normalized expression of Cpt the rate limiting enzyme in FAO (Fig. 6c). There was lower 
expression of apoptosis markers in tubules (cleaved caspase3 staining and Bcl2 expression, 
Fig. 6a,d) of the Ppargc1a transgenic animals. These results indicate that restoring FAO, but 
not glucose utilization (Fig. 6e) by Ppargc1a ameliorates fibrosis development.
Next, we examined whether pharmacological activation of Ppara can also protect mice from 
tubule epithelial fibrosis development using the folic acid-induced injury model. Animals 
were injected with fenofibrate starting one day prior to folic acid injection. Fenofibrate 
administration strongly induced the expression of FAO enzymes Cpt1, 2 and Acox1, 2 (Fig. 
6f). Folate-treated mice injected with fenofibrate had improved renal histology, lower 
expression of cleaved caspase 3 (Fig. 6g), reduced fibrosis, kidney injury, apoptosis rate 
(Fig. 6h), and improved renal function (Fig. 6i) compared to sham injected animals. On the 
other hand, enzymes level related to glucose utilization were not recovered by fenofibrate 
treatment (Fig. 6j). These observations were not limited to the folic acid induced kidney 
fibrosis model and similar results were observed upon analyzing the unilateral ureteral 
obstruction-(UUO) induced kidney fibrosis model. There was low expression of FAO-
related genes in the UUO model (Supplementary Fig. 9). Treatment with fenofibrate 
restored FAO related enzyme expression, lower expression of epithelial injury (Kim-1) and 
fibrosis markers (collagens) (Supplementary Fig. 9).
Next, to provide additional evidence that kidney fibrosis is specifically linked to a defect in 
FAO, we tested the effect of etoxomir; a specific inhibitor Cpt, the key enzyme in the FAO 
pathway. Mice treated with etomoxir developed more severe kidney injury after folic acid 
injection; they showed markedly higher expression of fibrosis markers and higher serum 
creatinine (Supplementary Fig. 10). Etomoxir inhibited Cpt and shifted metabolism to more 
glycolysis, evident by higher Glut1 and Pfk1 expression. However, the glycolytic phenotype 
did not improve (rather worsened) the fibrosis development.
In addition, we also tested the effect of C75, a synthetic compound that increases Cpt1 
activity and blocks fatty acid synthase28. C75 treatment restored expression of Cpt1 and 
Acox1, and markedly lowered apoptosis rate. C75 treatment improved kidney fibrosis and 
function (Supplementary Fig. 11) without restoring the defect in glucose utilization, 
indicating again the critical role of FAO in fibrosis development. In summary, our results 
indicate that improving FAO by genetic or pharmacological activation of Ppargc1a, Ppara or 
Cpt1 protects animals from fibrosis development.
Discussion
In this study we aimed to identify and examine common mechanisms of kidney fibrosis. 
Here we present genome-wide transcript data from a large human CKD kidney sample 
cohort. Our non-biased studies indicated consistent differences in two gene groups; 
inflammation and metabolism. Several metabolic pathways were dysregulated in kidney 
fibrosis. Carbohydrate, amino acid and lipid metabolism were markedly depressed in patient 
samples with fibrosis.
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Research into lipid metabolism in the kidney has been limited29,30. Clinical observations 
indicate a potential association between lipid levels and CKD development31. Most prior 
observations focused at higher lipid accumulation in TECs in CKD kidneys12,18. Higher 
intracellular lipid accumulation was proposed to play a key role in fibrosis development by 
inducing lipotoxicity12,20,32. Our results, however, indicate that higher intracellular 
triglyceride accumulation alone was not sufficient to induce the full spectrum of fibrosis in 
our CD36 transgenic mouse model and substrate (fatty acid) availability does not seem to be 
the limiting factor in kidney fibrosis. We also found that depressed FAO was associated with 
intracellular lipid accumulation (Supplementary Fig. 12). Our data therefore suggest a 
modest role for triglyceride accumulation in kidney fibrosis development.
We found that renal TEC critically depend on fatty acid oxidation as their energy source. 
This observation is in line with (almost half a century old) studies showing that kidneys 
preferentially take up and oxidize fatty acids and they are not a major contributor to 
circulating glucose catabolism33. As TECs are one of the highest energy demanding cells in 
the body, this carbon preference is quite logical. Other high-energy demanding organs (for 
example the heart) also depend on FAO24.
Increased glucose utilization is the key metabolic phenotype of renal cell cancer and 
polycystic kidney disease11,34,35. It is important to note that in fibrosis, tubule cells did not 
significantly revert to glucose oxidation. Additional genetic mutations or signaling 
mechanisms are likely needed to make this metabolic switch and simply loosing the capacity 
for FAO does not induce a change in energy substrate preference. Upon inhibition of FAO 
in TEC, cellular ATP level decreased, likely contributing to the increased apoptosis rate and 
dedifferentiation. The key observation of the current work is that the decreased FAO alone 
was sufficient to reprogram TEC cells into a profibrotic phenotype, while improving FAO 
restored cell differentiation.
We also found that TGFB1 appears to be an important upstream modulator of fatty acid 
metabolism in renal TECs. In TECs TGFB1 acted upstream of Ppargc1a. Chromatin 
immunoprecipitation studies indicate that Smad3 can directly bind to the Ppargc1a 
regulatory region36. A similar mechanism has already been described in adipocytes; a 
TGFB1-driven Smad3-dependent pathway appears to control Pgc1a and downstream fat 
deposition36. There might be other factors and cytokines that regulate Ppargc1a and FAO in 
kidney fibrosis (Supplementary Fig. 12), for example Lkb1 and Ampk could be important 
controllers of FAO in TECs37 (Drs. Han and Susztak unpublished observation). In our 
models and human samples, we did not observe a significant change in mitochondrial copy 
number, on the other hand the expression of several important mitochondrial genes was 
lower in fibrotic kidney samples. As beta-oxidation also takes places in the mitochondria we 
cannot exclude that the reduced FAO is just one manifestation of a broader mitochondrial 
dysfunction and/or oxidative phosphorylation defect. Mitochondrial dysfunction proposed to 
play important role in diabetic kidney disease development. Future studies shall determine 
the role of FAO and mitochondria in fibrosis development. Performing metabolic studies in 
glomerular cells and glomerular injury models will also be important.
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Our studies could have several important clinical implications. FAO inhibitors have received 
significant attention recently, when it was found that these drugs significantly sensitize 
leukemia cells for cell death because leukemia cells use fatty acid as their key energy 
substrate38. Short-term treatment of animals with FAO inhibitors did not induce kidney 
fibrosis, however mice treated with FAO inhibitors showed increased fibrosis following 
injury. Future studies shall determine the long-term renal consequences of fatty oxidation 
inhibitors.
On the other hand our experiments indicate that drugs that enhance FAO might be of 
therapeutic benefit for patients with kidney fibrosis. For example the Ppara agonist 
fenofibrate might confer therapeutic benefit for patients with chronic kidney disease, as 
fenofibrate is widely used clinically for the treatment of hyperlipidemia. Indeed, some long-
term studies indicate reduction in albuminuria in patients with type 2 diabetes39–41. 
Unfortunately, the effect of fibrates on renal function is less obvious as it can be associated 
with a rise in serum creatinine. Our results indicate that Ppargc1 or Cpt1 agonists might 
have a better therapeutic profile.
In summary, our studies show that decreased tubule epithelial FAO causes metabolic 
reprogramming of TECs inducing increased apoptosis and dedifferentiation. Restoring FAO 
could offer new therapeutic approaches for the treatment and prevention of kidney fibrosis.
Online Methods
Antibodies and reagents
PPARa (IHC, Abcam, #ab8934), PPARGC1A (IHC, Abcam, #ab54481), and Cleaved 
caspase 3 (IF, IHC, Cell signaling, #9662), RPMI 1640 (Cellgro), CD36 (WB, Santa Cruz 
#sc-7309), FBS (Atlanta Biologicals), EGF (Peprotech), bFGF (Peprotech), Penicilin 
Streptomycin (Cellgro), ITS (Cellgro), hydrocortisone (Sigma), TGFβ1 (Peprotech), 
fenofibrate (Sigma), etomoxir (Sigma), ranolazine (Sigma), RNAeasy mini columns 
(Qiagen, Valencia, CA), collagenase I (Worthington Biochemical Product), 100 µm mesh 
(Fisherbrand), doxycycline-containing chow (Bioserv S3888), oil red o (EMD chemical), 
palmitate conjugated BSA (Seahorse Bioscience), oligomycin (Seahorse Bioscience), DNP 
(Sigma), 2-DG (Sigma), and rotenone (Sigma).
Human kidney tissue handling and microdissection
Tissue was placed into RNALater and manually microdissected at 4°C for glomerular and 
tubular compartments as described earlier. Dissected tissue was homogenized and RNA was 
prepared using RNAeasy mini columns according to manufacturer’s instruction. RNA 
quality and quantity was determined using Lab-on-Chip Total RNA PicoKit (Agilent 
BioAnalyzer). Only samples without evidence of degradation were used.
Gene expression analysis using Affymetrix Arrays
Transcript levels were analyzed by Affymetrix U133A and 1.0ST arrays. Probes were 
prepared using Affymetrix 3’ IVT kit. After hybridization and scanning, raw data files were 
imported into Genespring GX software (Agilent Technologies, USA). Raw expression levels 
Kang et al. Page 9
Nat Med. Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
were normalized using RMA16 summarization algorithm. Genespring GX software was 
then used for statistical analysis; the data was above the 20th percentile when filtered by 
expression. We used a Benjamini-Hochberg multiple testing correction with a p-value<0.05. 
Heatmap of gene expression data were generated using unsupervised hierarchical clustering 
method calculated by squared Euclidean distances. The Database for Annotation, 
Visualization and Integrated Discovery13 bioinformatics package was also used for gene 
ontology and pathway analysis. In addition, the Ingenuity Pathway Analysis (IPA, Redwood 
City, CA) was used to generate networks.
Primary culture of human and mouse renal tubule cells
Kidneys were collected from the non-cancerous part of nephrectomies. Cell were isolated by 
2 mg ml−1 collagenase I digestion for 30 mins at 37 °C with gentle stirring and then filtered 
through the 100 µm mesh to collect single cells. Cell were cultured in RPMI 1640 
supplement with 10% FBS, 20 ng ml−1 EGF, 20ng ml−1 bFGF and 1 % Penicilin 
Streptomycin at 5% CO2, 37 °C. HKC8 cells were cultured in DMEM/F12 supplemented 
with 5 % FBS, 1X ITS, 0.5 ug ml−1 hydrocortisone and 1 % Penicilin Streptomycin at 5% 
CO2, 37 °C. At 80% confluence, cells were starved in 0.5% FBS (RPMI) overnight and 
treated with 50 ng ml−1 TGFB1 with or without 1µM fenofibrate, 40 µM etomoxir or 200 
µM ranolazine for 48h.
Animals
Male FvB mice (~25 gr, 6 weeks old), Pax8-rtTA transgenic mice and TRE-Pgc1a animals 
were purchased from Jackson Laboratory (Stock numbers 007176, 012387, respectively). 
Transgenic mice carrying the TRE-ICNotch 1 transgene were obtained from Dr D Melton 
(Harvard Medical School). Mice with TRE-hCD36 transgene will be described later (SH 
Ahn and Susztak unpublished observation). Briefly the human CD36 cDNA was cloned into 
the pTRE Tight vector (Clontech) and the construct was injected into FvB oocytes at the 
Einstein Transgenic facility. Transgenic mice were identified by genomic PCR analysis. 
Several founder lines were obtained and two lines with the highest expression of CD36 were 
kept for further analysis. We used human CD36 specific QRT-PCR primers and antibodies 
to distinguish endogenous (mouse) and transgene (human) expression. Mice were placed on 
doxycycline-containing chow starting at 3 weeks of age. Only male mice were used in the 
study. Mice (3–6 weeks of age) were injected with FA (250 mg kg−1, dissolved in 300 mM 
NaHCO3) or streptozotocin (50mg kg−1 for 5 days) intraperitoneally. One day before the FA 
injection, Ppara agonist fenofibrate (50mg kg−1 for 3 days and 100mg kg−1 for 5 days) was 
administered by oral gavage. Mice were randomly allocated to FA injected (FAN, n=5), FA 
with fenofibrate injected (FAN + fenofibrate, n=5) and sham-treated group (n=5). C75 
(15mg kg−1) was injected i.p one day before FA injection. Etomoxir (30mg kg−1 for 2 days) 
was injected i.p two day before the FA injection. For UUO experiments, fenofibrate (125mg 
kg−1) was administered for 10 days. The treatment was started 3 days before the surgery and 
ended on day 7. Under sterile conditions, animals were anaesthetized with a mixture of 
isoflurane and oxygen. UUO was performed by complete ligation of the left ureters with 6-0 
non-absorbable suture. Animal studies were approved by the Animal Care Committee of the 
University of Pennsylvania.
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QRT-PCR
RNA was isolated from harvested cells and kidneys using RNAeasy Mini kit. 1 µg RNA was 
reverse transcribed using cDNA archival kit (Life Technology) and QRT-PCR was run in 
the ViiA 7 System (Life Technology) machine using SYBRGreen Master Mix and gene 
specific primers. The data was normalized and analyzed using the delta delta CT method. 
Primers used are listed in Supplementary Table I.
Histology and immunostaining
We used formalin-fixed, paraffin-embedded kidney sections stained with periodic acid 
Schiff (PAS) and OCT embedded frozen sections for oil red o staining. We performed 
immunocyto- and -histochemistry on paraformaldehyde fixed cells and formalin- fixed, 
paraffin-embedded kidney sections. We used the following primary antibodies: PPARa 
(1:1,000), PPARGC1A (1:500), and Cleaved caspase 3 (1:1,000). Staining was visualized 
using peroxidase-conjugated antibodies to mouse immunoglobulin using the Vectastain Elite 
kit and 3,3-diaminobenzidine (DAB) (Vector Labs).
Gas chromatography followed by flame ion diffusion (GC/FID)
Analysis of fatty acid profiles of control (CTL) and hCD36 transgenic (TG) mice was done 
at the Metabolomics Core of the Diabetes Center of the Albert Einstein College of Medicine.
Measurement of oxygen consumption rate and extracellular acidification rate
A Seahorse Bioscience X24 extracellular flux analyzer was used to measure the rate change 
of dissolved O2 in medium immediately surrounding adherent cells cultured in an XF24 V7 
cell culture microplate (Seahorse Bioscience). Human and mouse primary tubular epithelial 
cells and HKC8 cultured in RPMI 1640 supplement with 0.5 % FBS with or without 50ng 
ml−1 TGFB1 or 1uM fenofibrate were seeded in XF24 V7 cell culture microplate at 1.0 × 
104 cells per well. Oxygen consumption rates (pmol min−1) and extracellular acidification 
rate were assessed at baseline and after the after the addition of palmitate conjugated BSA or 
10 mM glucose followed by the addiction of the carnitine palmitoyltransferase-1 (CPT1) 
inhibitor etomoxir or the mitochondrial upcoupler, 2-4 DNP or glycolysis inhibitor 2-DG. 
Final state was determined after the addition of the ATP synthase inhibitor oligomycin or 
rotenone.
ATP measurement
ATP content was determined using the ATP Colorimetric Assay kit (Biovision), following 
the manufacturer's instructions, on HKC8 cells treated with etomoxir or TGFB1.
Mitochondrial copy number determination
Mitochondrial copy number was determined using NovaQUANT™ Mitochondrial to 
Nuclear DNA Ratio Kit (Novagen) following the manufacturer's instructions using human 
and mouse kidney genomic DNA.
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Triglyceride measurement
Kidney triglyceride was measured using quantification kits (Cayman Chemical) according to 
the manufacturer’s instructions.
Statistical analyses
The data were presented as mean ± s.e.m. Unpaired student’s t-test was used for 
comparisons between two groups. When needed multiple testing correction was performed 
by one way ANOVA with Tukey’s post hoc tests. P value < 0.05 was considered to be 
significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The transcriptional landscape of human tubulointerstitial fibrosis
(a), Gene ontology analysis of human chronic kidney disease (CKD) samples. The graph 
shows the minus log p-values for the enrichment of a specific pathway. (b), Gene set 
enrichment analysis highlighted strong enrichment for FAO pathway in CKD human 
samples. (c), Heatmap analysis of transcripts expression related to fatty acid metabolism. 
(d), Relative mRNA levels of genes related to FAO in human control (CTL) and CKD 
samples (CPT1a; carnitine palmitoyl-transferase 1a, CPT2; carnitine palmitoyl-transferase 2, 
ACOX1; acyl-CoA oxidase 1, ACOX2; acyl-CoA oxidase 2, PPARa; Peroxisome 
proliferator-activated receptor alpha and PPARGC1a; peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha). (e), Representative images of control and CKD 
human kidney samples stained with periodic acid-schiff (PAS), PPARa and PPARGC1Aa 
and oil red o (lipid droplets). Scale bar, 20 µm. (f), Quantification of PPARa and 
PPARGC1a immunostaining in CTL and CKD human kidney samples. (g), Relative 
transcript levels of enzymes related to carbohydrate metabolism (HK; hexokinase, PFK; 
phosphofructokinase, GAPDH; Glyceraldehyde 3-phosphate dehydrogenase, PGK1; 
phosphoglycerate kinase 1, IDH1; isocitrate dehydrogenase 1, PK; pyruvate kinase and 
GLUT1; Glucose transporter 1). All data are presented as means as ± s.e.m (n=95, 59 of 
control and 36 of CKD), and * p<0.05 compare to CTL.
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Figure 2. Dysregulation of FAO in mouse models of tubulointerstitial fibrosis
(a), Representative images of PAS stained kidney sections of control and Pax8rtTA/
TREICNotch1 mice, followed by Ppara immunnostaining images. (b), Gene-ontology 
analysis of control and Pax8rtTA/TREICNotch1 mice. (c,d), Relative mRNA levels of genes 
related to FAO (Cpt1a; carnitine palmitoyl-transferase 1a, Cpt2; carnitine palmitoyl-
transferase 2, Acox1; acyl-CoA oxidase 1, Acox2; acyl-CoA oxidase 2, Ppara; Peroxisome 
proliferator-activated receptor alpha and Ppargc1a; peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha) and glucose utilization (Hk; hexokinase, Pgk1; 
phosphoglycerate kinase 1, Gapdh; Glyceraldehyde 3-phosphate dehydrogenase, Idh1; 
isocitrate dehydrogenase 1, Pk; pyruvate kinase and Glut1; Glucose transporter 1) in control 
(CTL) and mouse TIF (ICNotch1) samples. All data are presented as means as ± s.e.m (n=6, 
3 of control and 3 of Pax8rtTA/TREICNotch1 mice) and * p<0.05 compare to CTL. (e), 
Relative transcript levels of FAO related enzymes in control (CTL) and FA-induced TIF 
samples (FAN). All data are presented as means as ± s.e.m (n=12, 6 of control and 6 of FAN 
mice) and * p<0.05 compare to CTL. (f), Representative images of mouse kidney sections 
from control and folic acid induced nephropathy (FAN) with PAS staining, immunostaining 
for Ppara and Ppargc1a and Oil Red O staining. Scale bar, 20 µm. (g), Quantification of 
Ppara and Ppargc1a images in the CTL and FAN mouse kidney samples. (h), Triglyceride 
(TG) contents in mouse kidney tissue. N = 10, 4 of CTL and 6 of FAN. * p<0.05 compare to 
CTL.
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Figure 3. Role of tubular epithelial cell lipid accumulation in tubular interstitial fibrosis 
development
(a), Protein expression (Western blot) of human CD36 in control and Pax8rtTA/TRECD36 
mouse kidney samples. (b), Representative images of PAS, oil red o and Sirius red stained 
control and CD36 transgenic animals. Scale bar, 20 µm. (c), Triglyceride (TG) contents in 
mouse kidney tissue. N = 5 of CTL and n=5 of 20 week old human CD36 transgenic mice. * 
p<0.05. (d), Fatty acid quantification in the control and CD36 TG mice by GC/FID. (e–g), 
Quantitative RT-PCR analysis of transcripts of key FAO enzymes and regulators (Cpt1a; 
carnitine palmitoyl-transferase 1a, Cpt2; carnitine palmitoyl-transferase 2, Acox1; acyl-CoA 
oxidase 1, Acox2; acyl-CoA oxidase 2 and Ppara; Peroxisome proliferator-activated receptor 
alpha), markers of fibrosis (Vim; vimentin, Fn; fibronectin, Col1a1; collagen 1a1, Col3a1; 
collagen 3a1, Col4a1; collagen 4a1 and Acta2; alpha smooth muscle actin) and apoptosis 
markers (Apaf1; apoptosis inducing factor1, Bax; BCL2 associated X protein, Bcl2; B-cell 
CLL/ lymphoma 2) in 8 week and 20 week old human CD36 transgenic mice. All data are 
presented as means as ± s.e.m (n=17, n=5 control, n=5 Pax8rtTA/TRECD36 at 8 weeks, and 
n=7 of Pax8rtTA/TRECD36 at 20 weeks) and * p<0.05 compared to controls.
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Figure 4. Transforming growth factor beta 1 suppresses FAO in renal TEC
(a), Oxygen consumption rate (OCR) of human tubule epithelial cell line (HKC8); each 
data-point represents the mean (and S.E.M) of ten independent samples. When indicated 
palmitate (180 µM), etomoxir (40 µM), and oligomycin (1 µM) was added. (b), OCR and 
extracellular acidification rate (ECAR) of HKC8 were measured in a Seahorse XF24 
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analyzer. Each data-point represents the mean of ten independent samples. 10 mM glucose, 
2–4 dinitrophenol (2–4 DNP, 100 µM), 2-deoxyglucose (2-DG, 100 mM), and rotenone (1 
µM) were injected sequentially at the indicated time points. (c), ATP levels of control (CTL) 
HKC8 cells, and cells treated with 40 µM etomoxir (CPT1 inhibitor). (d), Bright field, oil 
red o staining and caspase 3 immunofluorescence images of HKC8 cells, untreated (left) or 
etomoxir treated (right). (e), Relative transcript amounts of genes related to apoptosis 
(APAF1; apoptosis inducing factor1, BAX; BCL2 associated X protein, BCL2; B-cell CLL/ 
lymphoma 2, BCL2L1; BCL2 like 1) of HKC8 cells upon etomoxir treatment (n=6, 3 of 
control and 3 of etomoxir treated cells). (f), QRT-PCR based relative mRNA levels of 
markers of cellular dedifferentiation (VIM; vimentin, FN; fibronectin, COL1; collagen1, 
COL3, collagen3, and ACTA2; alpha smooth muscle actin) of HKC8 cells treated with 
etomoxir. (g), OCR measurement of HKC8 exposed to 50ng ml−1 TGFβ1 for 48 hrs or 
controls. Representative traces are shown right, and summary data left analyzed for 16 wells 
from independent experiments. When indicated palmitate (180 µM), glucose (25mM) and 
oligomycin (1 µM) were added. (h), Relative mRNA amount of transcripts of FAO enzymes 
(CPT1a; carnitine palmitoyl-transferase 1a, CPT2; carnitine palmitoyl-transferase 2, 
ACOX1; acyl-CoA oxidase 1, ACOX2; acyl-CoA oxidase 2, PPARa; Peroxisome 
proliferator-activated receptor alpha and PPARGC1a; peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha) of control and TGFB1 treated cells. All experiments 
were replicated twice with triplicate repeated measures for each condition. (i), Lipid 
accumulation was determined by oil red O staining of control and TGFB1 treated cells. 
Scale bar, 20 µm (j), ATP levels of control (CTL) HKC8 cells, and cells treated with 
TGFB1. All data are presented as means as ± s.e.m (n=8, 4 of control and 4 of TGFB1) and 
* p<0.05.
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Figure 5. Transforming growth factor beta (TGFB1) suppresses FAO in a SMAD3 and 
PPARGC1A dependent manner
(a) The human PPARGC1A locus followed by SMAD2/3 ChIP-Seq, human kidney 
H3K4me1 and H3K4me3 ChIPSeq, human kidney specific gene regulatory region 
annotation (red promoter, yellow enhancer) followed by GERP-based conservation scoring. 
(b), OCR were measured in primary TEC from wild type (WT) and Pax8rtTA/
TREPPARGC1A (TG) mice treated or not with TGFB1. Representative traces are shown 
right and summary data on left analyzed for 12 wells for independent experiments. All data 
are presented as means as ± s.e.m and *p<0.05 compare to WT and ** p<0.05 compare to 
WT-TGF. When indicated palmitate (180 µM), glucose (25mM) and oligomycin (1 µM) 
were added. (c–d), Expression of key enzymes critically related to FAO and glucose 
utilization in primary renal tubule epithelial cell from Pax8rtTA/TREPPARGC1A transgenic 
mice (TG) or control (CTL) exposed with 50ng ml−1 TGFB1 for 48h (Cpt1a; carnitine 
palmitoyl-transferase 1a, Cpt2; carnitine palmitoyl-transferase 2, Acox1; acyl-CoA oxidase 
1, Acox2; acyl-CoA oxidase 2, Ppara; Peroxisome proliferator-activated receptor alpha and 
Ppargc1a; peroxisome proliferator-activated receptor gamma, coactivator 1 alpha, Hk; 
hexokinase, G6pc; glucose-6-phosphatase, catalytic subunit, Pfk1; phosphofructokinase 1, 
Idh2; isocitrate dehydrogenase 2, Pkm2; pyruvate kinase, muscle2, Glut1; glucose 
transporter 1). (e–f), Protection effects of Ppargc1a transgenic cells from TGFB1 induced 
fibrosis development including profibrotic, (Vim; vimentin, Fn; fibronectin, Col1a1; 
collagen 1a1, Col3a1; collagen 3a1, Col4a1; collagen 4a1 and Acta2; alpha smooth muscle 
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actin) and apoptosis related genes (Apaf1; apoptosis inducing factor1 and Bcl2; B-cell CLL/ 
lymphoma 2). All data are presented as means as ± s.e.m (n=12, 3 of each condition), * p < 
0.05 compare to WT and ** p<0.05 compare to WT-TGF. (g), OCR in HKC8 exposed to 
50ng ml−1 TGFB1 for 48hrs in the presence or absence of 1 µM fenofibrate. When indicated 
cells were incubated in palmitate (180 µM), glucose (25mM), and oligomycin (1 µM). (h–i), 
Relative mRNA expression of transcripts related to FAO, (CPT1a; carnitine palmitoyl-
transferase 1a, CPT2; carnitine palmitoyl-transferase 2, ACOX1; acyl-CoA oxidase 1, 
ACOX2; acyl-CoA oxidase 2, and PPARa; Peroxisome proliferator-activated receptor 
alpha), fibrosis and apoptosis (VIM; vimentin, FN; fibronectin, COL1A1; collagen1a, 
COL3A1; collagen3a1, COL4A1; collagen4a1, ACTA2; alpha smooth muscle actin, 
APAF1; apoptosis inducing factor1, and BCL2; B-cell CLL/ lymphoma 2) in HKC8 cells 
treated with or without TGFB1 and fenofibrate. All data are presented as means as ± s.e.m 
(n=9, 3 of control, 3 of TGFB1 and 3 of TGFB1 with fenofibrate treated group), *p<0.05 
compare to CTL and ** p<0.05 compare to TGFB1.
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Figure 6. Genetic or pharmacological restoration of FAO protects animals from fibrosis 
development
(a), Representative PAS, cleaved caspase 3 and Sirius Red stained kidney sections of control 
and FAN fibrosis model (day 7). We used wild type and single transgenic animals as 
controls (CTL, or FAN) and Pax8rtTA/TRE-PPARGC1A transgenic mice with folic acid 
(Ppargc1a FA). Scale bar, 20 µm. (b), Markedly lower expression of fibrosis related 
transcripts in PPARGC1A overexpressed mice followed by folic acid administration (Vim; 
vimentin, Fn; fibronectin, Col1a1; collagen 1a1, Col3a1; collagen 3a1, Col4a1; collagen 
4a1, Acta2; alpha smooth muscle actin, and Kim-1; kidney injury molecule-1). (c–e), 
Relative mRNA levels of FAO enzymes (Cpt1a; carnitine palmitoyl-transferase 1a, Cpt2; 
carnitine palmitoyl-transferase 2, Acox1; acyl-CoA oxidase 1, Acox2; acyl-CoA oxidase 2 
and Ppara; Peroxisome proliferator-activated receptor alpha), apoptosis associated markers 
(Apaf1; apoptosis inducing factor1, Bcl2; B-cell CLL/ lymphoma 2, and glucose utilization 
(Hk; hexokinase, G6pc; glucose-6-phosphatase, catalytic subunit, Pfk1; 
phosphofructokinase 1, Idh2; isocitrate dehydrogenase 2, Pkm2; pyruvate kinase, muscle2, 
Glut1; glucose transporter 1). All data are presented as means as ± s.e.m (n=18, 6 of control, 
6 of FAN and 6 of PPARGC1a FA group), * p<0.05 compare to CTL and ** p<0.05 
compare to FAN. (f), Relative mRNA levels of FAO enzymes in control (CTL) folic acid 
treated (FAN) and folic acid and fenofibrate treated (FAN+fenofibrate) mice. (g), Ppara 
agonist fenofibrate ameliorated fibrosis development in the FA induced fibrosis model. 
Representative PAS, cleaved caspase 3, oil red o and sirius red stained kidney sections. 
Scale bar, 20 µm. (h,i), Relative mRNA levels of fibrosis, apoptosis and glycolysis 
associated markers. All data are presented as means as ± s.e.m (n=14, 5 of control, 5 of FAN 
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and 4 of FAN with fenofibrate treated group) and * p<0.05. (j), Serum creatinine levels in 
CTL, FAN and FAN+fenofibrate mice. N = 15, 5 of CTL, 5 of FAN and 5 of FAN with 
fenofibrate mice. * p<0.05 compare to CTL and **p<0.05 compare to FAN.
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